A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

NCT04523207 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: Apalutamide
DRUG: ADT
DRUG: Relugolix

Sponsor

Janssen Research & Development, LLC